Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: Evidence for specificity toward P-450 2E1

Drug Metabolism and Disposition

Volumn 27, Issue 6, 1999, Pages 717-723

  Kharasch, Evan D ^a   Hankins, Douglas C ^b   Jubert, Carole ^b   Thummel, Kenneth E ^b   Taraday, Julie K ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; DEXTROMETHORPHAN; DIMETHYLNITROSAMINE DEMETHYLASE; DISULFIRAM; MEPHENYTOIN; MIDAZOLAM; TOLBUTAMIDE;

ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME INHIBITION; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DISULFIRAM; ENZYME INHIBITORS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; ISOENZYMES; MALE; MIXED FUNCTION OXYGENASES; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0032977948     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Beach CA, Mays DC, Guiler RC, Jacober CH and Gerber N (1986) Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics. Clin Pharmacol Ther 39:265-270.
2. Brady JF, Xiao F, Wang M-H, Li Y, Ning SM, Gapac JM and Yang CS (1991) Effects of disulfiram on hepatic P450IIE1, other microsomal enzymes, and hepatotoxicity in rats. Toxicol Appl Pharmacol 108:366-373.
3. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS and Guengerich FP (1989) Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28:4993-4999.
4. Caraco Y, Wilkinson GR and Wood AJ (1996) Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 60:396-404.
5. Chang TKH, Gonzalez FJ and Waxman DJ (1994) Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:437-442.
6. Chen ZR, Somogyi AA and Bochner F (1990) Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 12:97-104.
7. Csillag K, Vereczkey L and Gachalyi B (1989) Simple high-performance liquid chromatographic method for the determination of tolbutamide and its metabolites in human plasma and urine using photodiode-array detection. J Chromatogr 490:355-363.
8. Ducharme J, Abdullah S and Wainer IW (1996) Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B 678:113-128.
9. Enghusen Poulsen H, Loft S, Andersen JR and Andersen M (1992) Disulfiram therapy: Adverse drug reactions and interactions. Acta Psychiatr Scand 86 (Suppl 369):59-66.
10. Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP and Lin J-S (1993) Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 91:2150-2154.
11. Goldstein JA, Ishizaki T, Chiba K, de Morais SMF, Bell D, Krahn PM and Price Evans DA (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7:59-64.
12. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism and Biochemistry (Ortiz de Montellano PR ed), pp 473-535, Plenum Press, New York.
13. Guengerich FP, Kim D-H and Iwasaki M (1991) Role of human P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4:168-179.
14. Jacqz-Aigrain E, Funck-Brentano C and Cresteil T (1993) CYP2D6-dependent and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197-204.
15. Jacqz E, Hall SD, Branch RA and Wilkinson GR (1986) Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co-regulated substrate, mephobarbital. Clin Pharmacol Ther 39:646-653.
16. 2 by dithiocarbamates. Chem Res Toxicol 9:910-916.
17. Jones DR, Gorski JC, Haehner BD, O'Mara EM and Hall SD (1996) Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin Pharmacol Ther 60:374-384.
18. Kassai A, Toth G, Eichelbaum M and Klotz U (1988) No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. Clin Pharmacokinet 15:319-325.
19. Kharasch ED, Armstrong AS, Gunn K, Artru A and Cox K (1995) Clinical sevoflurane metabolism and disposition: II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation. Anesthesiology 82:1379-1388.
20. Kharasch ED, Hankins DC, Baxter PJ and Thummel KE (1998) Single-dose disulfiram does not inhibit CYP2A6 activity. Clin Pharmacol Ther 64:39-45.
21. Kharasch ED, Hankins D, Mautz D and Thummel KE (1996) Identification of the enzyme responsible for oxidative halothane metabolism: Implications for prevention of halothane hepatitis. Lancet 347:1367-1371.
22. Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle TA and Cox K (1997) The role of cytochrome P450 3A4 in alfentanil clearance: Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 87:36-50.
23. Kharasch ED, Thummel KE, Mautz D and Bosse S (1994) Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther 55:434-440.
24. Kharasch ED, Thummel K, Mhyre J and Lillibridge J (1993) Single-dose disulfiram inhibition of chlorzoxazone metabolism: A clinical probe for P450 2E1. Clin Pharmacol Ther 53:643-650.
25. Kubota T, Chiba K and Ishizaki T (1996) Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60:661-666.
26. Kupfer A and Preisig R (1984) Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26:753-759.
27. Lieber CS (1997) Cytochrome P-4502E1: Its physiological and pathological role. Physiol Rev 77:517-544.
28. Loft S, Sonne J, Pilsgaard H, Dossing M and Poulsen E (1986) Inhibition of antipyrine elimination by disulfiram and cimetidine: The effect of concomitant administration. Br J Clin Pharmacol 21:75-77.
29. Loi C-M, Day JD, Jue SG, Bush ED, Costello P, Dewey LV and Vestal RE (1989) Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. Clin Pharmacol Ther 45:476-486.
30. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ and Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298-305.
31. Olkkola KT, Backman JT and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485.
32. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ and Tsutsui M (1996) Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26:681-693.
33. Partovian C, Jacqz-Aigrain E, Keundjian A, Jaillon P and Funck-Brentano C (1995) Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans. Clin Pharmacol Ther 58:257-263.
34. Peart GF, Boutagy J and Shenfield GM (1987) Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. Eur J Clin Pharmacol 33:397-402.
35. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP and Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 3:565-573.
36. Petersen EN (1992) The pharmacology and toxicology of disulfiram and its metabolites. Acta Psychiatr Scand 86 (Suppl. 369):7-13.
37. Relling MV, Aoyama T, Gonzalez FJ and Meyer UA (1990) Tolbutamide and mephenytoin hydroxylation by human cytochrome-P450s in the CYP2C subfamily. J Pharmacol Exp Ther 252:442-447.
38. Schadel M, Wu D, Otton SV, Kalow W and Sellers EM (1995) Pharmacokinetics of dextromethorphan and metabolites in humans: Influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol 15:263-269.
39. Schmid B, Bircher J, Preisig R and Kupfer A (1985) Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-624.
40. Simon P, Nicot T and Dieudonné M (1994) Dietary habits, a non-negligible source of 2-thiothiazolidine-4-carboxylic acid and possible overestimation of carbon disulfide exposure. Int Arch Occup Environ Health 66:85-90.
41. Sohn DR, Kusaka M, Ishizaki T, Shin SG, Jang IJ, Shin JG and Chiba K (1992) Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 52:160-169.
42. Svendsen TL, Kristensen MB, Hansen JM and Skovsted L (1976) The influence of disulfiram on the half-life and metabolic clearance rate of diphenylhydantoin and tolbutamide in man. Eur J Clin Pharmacol 9:439-441.
43. Thummel KE, Shen DD, Podoll T, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, Perkins JD and Carithers RL (1994a) Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter-and intra-individual hepatic CYP3A variability following liver transplantation. J Pharmacol Exp Ther 271:557-566.
44. Thummel KE, Shen DD, Podoll T, Kunze KL, Trager WF, Hartwell P, Raisys V, Marsh CL, McVicar JP, Barr DM, Perkins JD and Carithers RL (1994b) Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271:549-556.
45. van Doorn R, Delbressine LPC, Leijdekkers C-M, Vertin PG and Henderson PT (1981) Identification and determination of 2-thiothiazolidine-4-carboxylic acid in urine of workers exposed to carbon disulfide. Arch Toxicol 47:51-58.
46. van Doorn R, Leijdekkers C-M, Nossent SM and Henderson PT (1982) Excretion of TTCA in human urine after administration of disulfiram. Toxicol Lett 12:59-64.
47. Veronese ME, Miners JO, Randles D, Gregov D and Birkett DJ (1990) Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 47:403-411.
48. Veronese ME, Miners JO, Rees DLP and Birkett DJ (1993) Tolbutamide hydroxylation in humans: Lack of bimodality in 106 healthy subjects. Pharmacogenetics 3:86-93.
49. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR and Branch RA (1984) Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 36:773-780.
50. Wilkinson GR, Guengerich FP and Branch RA (1989) Genetic polymorphism of S-mephenytoin hydroxylation. Phamacol Ther 43:53-76.
51. Wrighton SA, Stevens JC, Becker GW and Vandenbranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin-4′-hydroxylation. Arch Biochem Biophys 306:240-245.
52. Wrighton SA, VandenBranden M and Ring BJ (1996) The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 24:461-473.
53. Xie H-G, Huang S-L, Xu Z-H, Xiao Z-S, He N and Zhou H-H (1997) Evidence for the effect of gender on activity of (S)-mephenytoin 4′-hydroxylase (CYP2C19) in a Chinese population. Pharmacogenetics 7:115-119.
54. Xie H-G, Huang S-L and Zhou H-H (1995) High-performance liquid chromatographic determination of urinary 4′-hydroxymephenytoin, a metabolic marker for the hepatic enzyme CYP2C19, in humans. J Chromatogr B 668:125-131.
55. Yamazaki H, Inui Y, Yun C-H, Guengerich FP and Shimada T (1992) Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13:1789-1794.
56. Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ and Smith RA (1992) Dextromethorphan: Enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 51:647-655.